2011 Preview: Will Korean Pharmas Follow Japanese Pharmas Lead To Survive Harsh Environment At Home?
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Pricing pressure and increased government oversight of irregular business activities could prompt Korean pharmaceutical companies to focus on new growth strategies for 2011 such as cooperative deals with multinational companies and exports into new emerging markets like China, according to Korean analysts
You may also be interested in...
Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex
SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex
Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex
SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex
Korea FDA To Approve First Stem Cell Therapy For Myocardial Infarction
SEOUL - In what might be marked as the world's first approved stem-cell medication, Korea FDA plans to approve in early July Hearticellgram-AMI, a stem cell therapy for acute myocardial infarction, developed by Korean bioventure FCB-Pharmicell